Best Peptides for Appetite Control

Active ingredient in Ozempic/Wegovy. Mimics GLP-1 to signal fullness and slow gastric emptying. STEP trials showed 14.9% weight loss at 68 weeks.

Active ingredient in Mounjaro/Zepbound. Dual GLP-1/GIP agonist — more effective than semaglutide. SURMOUNT-1 showed up to 22.5% weight loss at 72 weeks.

Next-gen triple agonist from Eli Lilly hitting GLP-1, GIP, and glucagon receptors. Phase 2 showed 24.2% weight loss at 48 weeks — highest of any incretin therapy. At low doses, optimizes metabolism without major weight loss.

Semaglutide + cagrilintide combo in Phase 3 trials. Strongest weight loss data of any injectable to date, surpassing semaglutide alone through dual appetite/satiety targeting.

Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim. The glucagon component adds liver fat reduction, promising for fatty liver disease alongside obesity.

Dual GLP-1/glucagon receptor drug from Innovent Biologics. Strong weight loss and metabolic results. Already approved in China for obesity.

First oral non-peptide GLP-1 agonist in late-stage trials. A daily pill alternative to injectable GLP-1s with promising early weight loss data.

FDA-approved GH booster for reducing visceral belly fat in HIV-associated lipodystrophy. Trials showed ~15-18% visceral fat reduction. Overall weight loss is modest vs GLP-1 agonists.

Mitochondrial DNA-encoded peptide that activates AMPK, improving insulin sensitivity, fat burning, and mimicking exercise at the cellular level. Stacks well with SS-31 and NAD+.